Status: Not yet recruiting
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
This is a phase 1/2, open-label, single arm, multicenter study in patients with advanced or metastatic HPV16- or HPV52-positive carcinomas who have progressed after at least one line of systemic therapy, including but not limited to combination chemotherapy and/or combination chemo-immunotherapy
Participants needed: 66
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: SCG Cell Therapy Pte. Ltd.Updated: Jul 17, 2024
Eligibility criteria
Histologically confirmed squamous cell carcinoma (SCC); may include any of the f... [+7]
Presence of clinically relevant or active seizure disorder, stroke, cerebrovascu... [+11]